Stocktoria
Akari Therapeutics Plc AKTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-01-31
Akari Therapeutics Plc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $2.8M | $7.0M | $5.5M | $9.6M | $9.1M |
| SG&A expense | $9.3M | $9.7M | $11.4M | $13.5M | $8.1M |
| Operating income | -$17.3M | -$21.6M | -$16.8M | -$23.1M | -$17.2M |
| Interest expense | $100,000 | — | — | — | — |
| Income tax | -$1.0M | $0 | $0 | $0 | $0 |
| Net income | -$17.3M | -$19.8M | -$10.0M | -$17.7M | -$17.4M |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | -$10.6M | -$12.6M | -$16.4M | -$21.5M | -$18.8M |
| Cash & equivalents | $5.2M | $0 | $3.8M | $13.2M | $9.4M |
| Total assets | $47.9M | $50.6M | $4.4M | $13.8M | $11.6M |
| Total liabilities | $19.6M | $28.3M | $4.6M | $12.0M | $6.1M |
| Shareholders' equity | $28.3M | $22.2M | -$229,000 | $1.8M | $5.6M |
Source: SEC EDGAR filings · CIK 0001541157 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.